2023
Cardiology Encounters for Underrepresented Racial and Ethnic Groups with Human Immunodeficiency Virus and Borderline Cardiovascular Disease Risk
Bloomfield G, Hill C, Chiswell K, Cooper L, Gray S, Longenecker C, Louzao D, Marsolo K, Meissner E, Morse C, Muiruri C, Thomas K, Velazquez E, Vicini J, Pettit A, Sanders G, Okeke N. Cardiology Encounters for Underrepresented Racial and Ethnic Groups with Human Immunodeficiency Virus and Borderline Cardiovascular Disease Risk. Journal Of Racial And Ethnic Health Disparities 2023, 11: 1509-1519. PMID: 37160576, PMCID: PMC10632543, DOI: 10.1007/s40615-023-01627-0.Peer-Reviewed Original ResearchBody mass indexCVD riskCardiovascular diseaseCVD risk factor managementCox proportional hazards regressionHigher body mass indexUrban residenceRisk factor managementCardiovascular disease riskHuman immunodeficiency virusProportional hazards regressionAssociation of patientHigh-risk individualsAcademic medical centerAmbulatory visitsMedian ageMass indexProvider factorsAtrial fibrillationHazards regressionImmunodeficiency virusResultsA totalFactor managementInsurance typeMedical Center
2019
Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study
Butler J, Greene SJ, Shah SH, Shah SJ, Anstrom KJ, Kim RJ, Kalogeropoulos AP, Velazquez EJ, Hernandez AF, Desvigne-Nickens P, Scherzer R, Hsue PY, Braunwald E. Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. Journal Of Cardiac Failure 2019, 26: 371-380. PMID: 31682908, PMCID: PMC7195219, DOI: 10.1016/j.cardfail.2019.10.011.Peer-Reviewed Original ResearchConceptsDiastolic dysfunctionBody mass indexAntiretroviral therapyN-terminal pro-B-type natriuretic peptide levelsPro-B-type natriuretic peptide levelsHuman immunodeficiency virus-infected individualsCross-sectional case-control studyLow-density lipoprotein levelsHigher body mass indexHigh-sensitivity troponin IHIV RNA copiesSignificant valvular diseaseNatriuretic peptide levelsHigher interleukin-6Normal ejection fractionVirus-infected individualsLeft atrial sizePersistent atrial fibrillationProgressive cardiac remodelingSymptom frequency scoreAntiretroviral Therapy studyCardiac magnetic resonanceCase-control studyCarboxyl-terminal telopeptideCD4 count
2018
Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization
Piña IL, Zheng Q, She L, Szwed H, Lang IM, Farsky PS, Castelvecchio S, Biernat J, Paraforos A, Kosevic D, Favaloro LE, Nicolau JC, Varadarajan P, Velazquez EJ, Pai RG, Cyrille N, Lee KL, Desvigne-Nickens P. Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization. Circulation 2018, 137: 771-780. PMID: 29459462, PMCID: PMC5896331, DOI: 10.1161/circulationaha.117.030526.Peer-Reviewed Original ResearchConceptsIschemic left ventricular dysfunctionLeft ventricular dysfunctionCause mortalityCardiovascular mortalitySTICH trialSurgical deathsVentricular dysfunctionCardiovascular hospitalizationRisk factorsKansas City Cardiomyopathy Questionnaire overall summary scoreHigher New York Heart Association classCardiac Operative Risk Evaluation scoreCoronary artery disease risk factorsNew York Heart Association classHigher body mass indexComposite of deathCoronary artery bypassIschemic heart failureDisease risk factorsPoor prognostic factorVentricular ejection fractionCoronary artery diseaseBody mass indexLong-term outcomesOverall summary score
2016
Clinical and echocardiographic predictors of mortality in acute pulmonary embolism
Dahhan T, Siddiqui I, Tapson VF, Velazquez EJ, Sun S, Davenport CA, Samad Z, Rajagopal S. Clinical and echocardiographic predictors of mortality in acute pulmonary embolism. Cardiovascular Ultrasound 2016, 14: 44. PMID: 27793158, PMCID: PMC5086059, DOI: 10.1186/s12947-016-0087-y.Peer-Reviewed Original ResearchConceptsAcute pulmonary embolismChronic obstructive pulmonary diseaseBody mass indexTricuspid annular plane systolic excursionPulmonary artery acceleration timePulmonary embolismActive malignancyEjection fractionClinical parametersMass indexNYHA class III symptomsRV myocardial performance indexAnnular plane systolic excursionLeft ventricular ejection fractionMedian body mass indexClass III symptomsFraction area changeRV Tei indexSpeckle-tracking strainOutcomes of patientsAbsence of hypertensionTroponin T levelsMyocardial performance indexObstructive pulmonary diseaseSystolic blood pressure
2012
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. The Lancet 2012, 381: 537-545. PMID: 23219284, DOI: 10.1016/s0140-6736(12)61343-9.Peer-Reviewed Original ResearchConceptsCardiovascular event ratesBody mass indexNormal weightPrimary endpointObese patientsEvent ratesCardiovascular outcomesCardiovascular protectionHypertension treatmentObese individualsHigher cardiovascular event ratesHigh-risk hypertensive patientsNon-fatal myocardial infarctionAmlodipine-based therapyAvoiding Cardiovascular EventsPatient’s cardiovascular outcomeSuperior cardiovascular protectionSystolic Hypertension (ACCOMPLISH) trialPrimary event rateSingle-pill combinationPrevious clinical trialsNormal weight categoryCardiovascular deathCardiovascular eventsHypertension trials
2007
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk
Weber MA, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K, Investigators F. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. Blood Pressure 2007, 16: 13-19. PMID: 17453747, DOI: 10.1080/08037050701217643.Peer-Reviewed Original ResearchConceptsBody mass indexHigh cardiovascular riskCardiovascular eventsHypertensive patientsCardiovascular riskDiabetes mellitusCombination therapyNon-fatal cardiovascular endpointsCoronary artery bypass graftMean body mass indexAnti-lipid therapyAvoiding Cardiovascular EventsOral diabetes therapyPrevious antihypertensive treatmentSystolic Hypertension (ACCOMPLISH) trialDouble-blind treatmentAcute coronary syndromeArtery bypass graftAntihypertensive combination therapyHistory of strokePercutaneous coronary interventionAnti-platelet agentsACCOMPLISH trialAntihypertensive treatmentCardiovascular morbidity